Characterization of the immune response in patients with urothelial cell carcinoma of the bladder and during the BCG immunotherapy of bladder cancer
- Conditions
- C67Malignant neoplasm of bladder
- Registration Number
- DRKS00003700
- Lead Sponsor
- Chirurgische Universitätsklinik, Abteilung für Urologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 410
Inclusion Criteria
All patients undergoing treatment for urothelial cancer in the urologic department
Exclusion Criteria
Patients with compromised immune status, eg. AIDS, aquired immunodeficiency
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of a serological marker for bladder cancer
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive BCG-induced immune activation in urothelial cell carcinoma of the bladder?
How does BCG immunotherapy's immune response profile compare to standard-of-care treatments for non-muscle invasive bladder cancer?
Which biomarkers, such as PD-L1 expression or T-cell infiltration, predict response to BCG immunotherapy in bladder urothelial cell carcinoma patients?
What are the common immune-related adverse events associated with BCG immunotherapy for bladder cancer and their management strategies?
Are there combination therapies involving BCG and PD-1/PD-L1 inhibitors that enhance anti-tumor immunity in bladder cancer?